ADMA BIOLOGICS, INC. Sales Revenue, Goods, Net (Deprecated 2018-01-31)
ADMA BIOLOGICS, INC. (ADMA) reported Sales Revenue, Goods, Net (Deprecated 2018-01-31) of $2.33 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SalesRevenueGoodsNet · last filed 2018-05-14
- ADMA BIOLOGICS, INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $2.33M, a 11.28% increase year-over-year.
- ADMA BIOLOGICS, INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $3.40M, a 28.91% increase year-over-year.
- ADMA BIOLOGICS, INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $2.81M, a 23.89% increase year-over-year.
- ADMA BIOLOGICS, INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $2.36M, a 32.59% increase year-over-year.
- ADMA BIOLOGICS, INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2017 was $10.66M, a 21.94% increase from fiscal 2016.
- ADMA BIOLOGICS, INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2016 was $8.75M.
| Period end | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 3 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 6 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 9 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2018-03-31 | $2.33M 10-Q · filed 2018-05-14 | $5.73M derived: sum of 2 quarters · filed 2018-05-14 | $8.54M derived: sum of 3 quarters · filed 2018-05-14 | $10.90M derived: sum of 4 quarters · filed 2018-05-14 |
| 2017-12-31 | $3.40M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-29 | $6.21M derived: sum of 2 quarters · filed 2018-03-29 | $8.57M derived: sum of 3 quarters · filed 2018-03-29 | $10.66M 10-K · filed 2018-03-29 |
| 2017-09-30 | $2.81M 10-Q · filed 2017-11-03 | $5.17M derived: sum of 2 quarters · filed 2017-11-03 | $7.26M 10-Q · filed 2017-11-03 | $9.90M derived: sum of 4 quarters · filed 2018-05-14 |
| 2017-06-30 | $2.36M 10-Q · filed 2017-08-11 | $4.45M 10-Q · filed 2017-08-11 | $7.09M derived: sum of 3 quarters · filed 2018-05-14 | $9.36M derived: sum of 4 quarters · filed 2018-05-14 |
| 2017-03-31 | $2.09M 10-Q · filed 2018-05-14 | $4.73M derived: sum of 2 quarters · filed 2018-05-14 | $7.00M derived: sum of 3 quarters · filed 2018-05-14 | $8.78M derived: sum of 4 quarters · filed 2018-05-14 |
| 2016-12-31 | $2.64M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-29 | $4.91M derived: sum of 2 quarters · filed 2018-03-29 | $6.69M derived: sum of 3 quarters · filed 2018-03-29 | $8.75M 10-K · filed 2018-03-29 |
| 2016-09-30 | $2.27M 10-Q · filed 2017-11-03 | $4.05M derived: sum of 2 quarters · filed 2017-11-03 | $6.11M 10-Q · filed 2017-11-03 | |
| 2016-06-30 | $1.78M 10-Q · filed 2017-08-11 | $3.84M 10-Q · filed 2017-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |